$-0.34 EPS Expected for NewLink Genetics (NLNK); Fts International (FTSI) SI Increased By 9.74%

NewLink Genetics Corporation (NASDAQ:NLNK) Logo

Fts International Inc (NYSE:FTSI) had an increase of 9.74% in short interest. FTSI’s SI was 2.23M shares in February as released by FINRA. Its up 9.74% from 2.04 million shares previously. With 561,500 avg volume, 4 days are for Fts International Inc (NYSE:FTSI)’s short sellers to cover FTSI’s short positions. The SI to Fts International Inc’s float is 6.93%. The stock increased 13.08% or $1.04 during the last trading session, reaching $8.99. About 331,776 shares traded. FTS International, Inc. (NYSE:FTSI) has 0.00% since February 11, 2018 and is . It has by 0.00% the S&P500. Some Historical FTSI News: 30/04/2018 – FTS International 1Q Rev $467.5M; 21/04/2018 – DJ FTS International Inc, Inst Holders, 1Q 2018 (FTSI); 10/05/2018 – PSP Adds FTS International Inc., Exits Venator Materials: 13F; 05/03/2018 FTS INTERNATIONAL INC FTSI.N : CREDIT SUISSE RAISES TARGET PRICE TO $27 FROM $26; 18/04/2018 – FTS International Closes Above 50-Day Moving Average; 10/05/2018 – FTS International Closes Below 50-Day Moving Average; 30/04/2018 – FTS International 1Q Net $78.7M

Analysts expect NewLink Genetics Corporation (NASDAQ:NLNK) to report $-0.34 EPS on March, 7.They anticipate $0.03 EPS change or 8.11% from last quarter’s $-0.37 EPS. After having $-0.20 EPS previously, NewLink Genetics Corporation’s analysts see 70.00% EPS growth. It closed at $1.49 lastly. It is down 77.74% since February 11, 2018 and is downtrending. It has underperformed by 77.74% the S&P500. Some Historical NLNK News: 16/05/2018 – NewLink Genetics Announces Final Results from Phase 2 Studies of lndoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO 2018; 21/03/2018 – NewLink Genetics Appoints Chad A. Johnson to Board of Directors; 16/05/2018 – NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cance; 06/04/2018 – NEWLINK GENETICS REPORTS REVIEW OF CLINICAL PROGRAMS; 25/04/2018 – NewLink Genetics Announces Presentation of Abstracts at ASCO 2018 Annual Meeting; 10/05/2018 – Exelixis Says Combination of Atezolizumab and Cobimetinib Didn’t Deliver an Improvement in Overall Survival Versus Regorafenib; 17/04/2018 – NewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster Presentation; 12/03/2018 – NewLink Genetics to Participate in Upcoming Investor Conferences; 15/03/2018 – Factors of Influence in 2018, Key Indicators and Opportunity within NewLink Genetics, Chipmos Technologies, Helen of Troy, Inte; 10/05/2018 – EXELIXIS INC – GENENTECH INFORMED CO COMBINATION OF ATEZOLIZUMAB AND COBIMETINIB DID NOT DELIVER IMPROVEMENT IN OVERALL SURVIVAL VS REGORAFENIB

More notable recent NewLink Genetics Corporation (NASDAQ:NLNK) news were published by: Globenewswire.com which released: “NewLink Genetics to Participate in the Immuno-Oncology 360° Conference – GlobeNewswire” on January 30, 2019, also Nasdaq.com with their article: “NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 – Nasdaq” published on February 07, 2019, Uk.Finance.Yahoo.com published: “Before You Buy NewLink Genetics Corporation (NASDAQ:NLNK), Consider Its Volatility – Yahoo Finance UK” on January 22, 2019. More interesting news about NewLink Genetics Corporation (NASDAQ:NLNK) were released by: Seekingalpha.com and their article: “NewLink Genetics (NLNK) Presents At Baird’s Global Healthcare Conference – Slideshow – Seeking Alpha” published on September 05, 2018 as well as Seekingalpha.com‘s news article titled: “So At What Point Is NewLink Going To Be Safe To Re-Enter? – Seeking Alpha” with publication date: October 03, 2018.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $55.47 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.

Investors sentiment decreased to 0.69 in 2018 Q3. Its down 0.11, from 0.8 in 2018Q2. It is negative, as 22 investors sold NewLink Genetics Corporation shares while 20 reduced holdings. 12 funds opened positions while 17 raised stakes. 13.36 million shares or 6.48% less from 14.29 million shares in 2018Q2 were reported. Financial Bank Of America De has invested 0% in NewLink Genetics Corporation (NASDAQ:NLNK). 21,464 were accumulated by State Board Of Administration Of Florida Retirement Sys. Fifth Third Retail Bank holds 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK) for 1,000 shares. Fenimore Asset reported 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Blackrock has 2.26M shares for 0% of their portfolio. Marshall Wace Llp reported 102,008 shares. Strs Ohio has invested 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Deutsche State Bank Ag reported 0% stake. Stifel Finance stated it has 21,300 shares or 0% of all its holdings. Citigroup Incorporated invested 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK). Us National Bank & Trust De reported 3,243 shares or 0% of all its holdings. Pura Vida Invests Lc has invested 0.03% in NewLink Genetics Corporation (NASDAQ:NLNK). American Int Grp Incorporated holds 0% or 19,311 shares. Axa reported 256,700 shares. State Of Wisconsin Inv Board invested in 17,000 shares or 0% of the stock.

More notable recent FTS International, Inc. (NYSE:FTSI) news were published by: Prnewswire.com which released: “FTS International (FTSI) Alert: Johnson Fistel Announces Investigation of FTS International, Inc.; Encourages Investors to Contact the Firm for Additional Information – PRNewswire” on January 25, 2019, also Prnewswire.com with their article: “Scott+Scott Attorneys at Law LLP Announces Investigation into FTS International, Inc. (FTSI) – PRNewswire” published on January 24, 2019, Benzinga.com published: “Mid-Morning Market Update: Markets Rise; Exxon Mobil Earnings Top Estimates – Benzinga” on February 01, 2019. More interesting news about FTS International, Inc. (NYSE:FTSI) were released by: Seekingalpha.com and their article: “Dig Into FTS International – Seeking Alpha” published on October 22, 2018 as well as Seekingalpha.com‘s news article titled: “FTS International’s Worries Are Not Over Yet – Seeking Alpha” with publication date: December 13, 2018.

NewLink Genetics Corporation (NASDAQ:NLNK) Institutional Positions Chart